Cassava Sciences, Inc. (SAVA)


+0.57 (+2.87%)
Symbol SAVA
Price $20.42
Beta 0.695
Volume Avg. 1.49M
Market Cap 818.799M
Shares () -
52 Week Range 13.84-124.79
1y Target Est -
DCF Unlevered SAVA DCF ->
DCF Levered SAVA LDCF ->
ROE -17.93% Sell
ROA -19.00% Sell
Operating Margin -
Debt / Equity 2.99% Neutral
P/E -
P/B 3.44 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest SAVA news

Mr. Remi Barbier
NASDAQ Capital Market

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.